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Abstract
Background: Post-term pregnancy is associated with an increased risk of maternal complications, respiratory
distress and trauma to the neonate. Amniotic membrane sweeping has been recommended as a simple procedure
to promote the spontaneous onset of labour. However, despite its widespread use, there is an absence of evidence
on (a) its effectiveness and (b) its optimal timing and frequency. The primary aim of the MILO Study is to inform
the optimal design of a future definitive randomised trial to evaluate the effectiveness (including optimal timing
and frequency) of membrane sweeping to prevent post-term pregnancy. We will also assess the acceptability and
feasibility of the proposed trial interventions to clinicians and women (through focus group interviews).
Methods/design: Multicentre, pragmatic, parallel-group, pilot randomised controlled trial with an embedded
factorial design. Pregnant women with a live, singleton foetus ≥ 38 weeks gestation; cephalic presentation;
longitudinal lie; intact membranes; English speaking and ≥ 18 years of age will be randomised in a 2:1 ratio to
membrane sweep versus no membrane sweep. Women allocated randomly to a sweep will then be randomised
further (factorial component) to early (from 39 weeks) versus late (from 40 weeks) sweep commencement and a
single versus weekly sweep. The proposed feasibility study consists of four work packages, i.e. (1) a multicentre, pilot
randomised trial; (2) a health economic analysis; (3) a qualitative study; and (4) a study within the host trial (a
SWAT). Outcomes to be collected include recruitment and retention rates, compliance with protocol, randomisation
and allocation processes, attrition rates and cost-effectiveness. Focus groups will be held with women and clinicians
to explore the acceptability and feasibility of the proposed intervention, study procedures and perceived barriers
and enablers to recruitment.
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Discussion: The primary aim of the MILO Study is to inform the optimal design of a future definitive randomised
trial to evaluate the effectiveness (including optimal timing and frequency) of membrane sweeping to prevent
post-term pregnancy. Results will inform whether and how the design of the definitive trial as originally envisaged
should be delivered or adapted.
Trial registration: ClinicalTrials.gov NCT04307199. Registered on 12 March 2020
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Background
Labour and childbirth are physiological processes, and for
the majority of women, the onset of labour is spontan-
eous. However, some women will have an induction of
labour. Induction of labour is the process of artificially
stimulating uterine contractions to initiate the onset of
labour. Approximately one in four pregnancies in the de-
veloped world will end with an induction of labour [1, 2].
Current World Health Organization guidelines note that
induction of labour, as with any intervention, carries risks
and advise that induction of labour is not recommended
for women with uncomplicated pregnancies less than 41
weeks gestation [2]. Conversely, in response to the find-
ings of recent studies which report that elective pharma-
cological induction of labour results in a lower risk of
caesarean section than expectant management, the Ameri-
can College of Obstetricians and Gynecologists has
amended their guidance to support elective induction of
labour of low-risk women, having their first baby, at 39
weeks gestation [3–5]. Medical indications for induction
of labour include preterm premature rupture of mem-
branes (PPROM), intrauterine growth restriction, hyper-
tensive disorders of pregnancy, intrauterine foetal death
and post-term pregnancies [6]. Of these, post-term preg-
nancy is the most common [7, 8].
A pregnancy is considered to have reached full term at
37 completed week’s gestation; however, some pregnan-
cies will continue past 41 weeks’ completed gestation
and are then considered ‘post-term’ [9]. The rates of
post-term pregnancy, defined as a pregnancy that has
reached 42 weeks gestation from the last menstrual
period (LMP), vary worldwide (0.2% in Belgium, 5.8% in
the USA, 7% in Sweden) [9–12]. Birth post 42 weeks’
gestation carries an increased risk for the neonate in-
cluding increased risk of meconium aspiration, neonatal
acidaemia, low Apgar scores, macrosomia and neonatal
death [13, 14]. The incidence of maternal complications
such as severe perineal injury (third- and fourth-degree
perineal lacerations) related to macrosomia, post-partum
haemorrhage, chorioamnionitis and endomyometritis is
increased post-term [15].
Labour may be induced using pharmacological, surgi-
cal and mechanical methods.
1. Pharmacological methods include the use of
prostaglandins, such as dinoprostone administered
either vaginally or intracervically; misoprostol
administered orally, vaginally or intracervical; and
oxytocin administered intravenously [16].
Pharmacological methods of induction of labour are
not suitable for all women [17]. Reduced levels of
prostaglandins are indicated in women with high
parity, and the use of prostaglandins is
contraindicated in cases of women with a previous
caesarean section [17]. Pharmacological induction
of labour increases the risk of uterine
hyperstimulation [17].
2. Surgically, labour may be induced using procedures
including the deliberate rupturing of the amniotic
membranes known as amniotomy [18]. Amniotomy
carries the risk of umbilical cord prolapse and is
contraindicated when the presenting part of the
foetus is not engaged in the pelvis and in women
with a history of placenta praevia and vasa praevia.
It also increases the risk of infection for the mother
and foetus and is contraindicated in HIV-positive
women [19, 20].
3. Mechanical methods of induction of labour are
used to ripen and dilate the cervix encouraging the
spontaneous onset of labour through manual
manipulation of the cervix [21]. Mechanical
methods include the use of an intracervical Foley
catheter and amniotic membrane sweeping, also
referred to as ‘stripping’ or ‘stretch and sweep’ of
the membranes.
This study seeks to evaluate the role of membrane
sweeping.
Description of the intervention
An amniotic membrane sweep is performed with con-
sent during a vaginal examination. It involves the clin-
ician inserting one or two fingers into the woman’s
cervix and detaching the inferior pole of the membranes
from the lower uterine segment in a circular motion
[22]. Membrane sweeping is a simple procedure and
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may be used independently or in combination with other
means of induction and can be repeated multiple times.
How the intervention might work
Amniotic membrane sweeping is used to promote the
onset of labour by releasing localised prostaglandins
F2α, phospholipase A2 and cytokines from the intrauter-
ine tissues [23]. These hormones act on the cervix to
augment cervical ripening potentially instigating uterine
contractions. The manual stretching of the cervix may
help to initiate the Ferguson reflex by releasing oxytocin
thereby increasing uterine activity [23]. The aim of am-
niotic membrane sweeping is to soften and ripen the
cervix, increasing cervical favourability and stimulate
spontaneous uterine contractions potentially leading to
the onset of labour and avoidance of a formal induction
of labour.
Why is this research needed?
Post-term pregnancy is by far the most common reason
for induction of labour, and membrane sweeping offers
a potentially low-risk method to reduce this. Membrane
sweeping is a technically simple intervention and may be
performed by clinicians in a community or clinical set-
tings potentially providing significant reductions in cost
[17, 24]. Recent studies have supported elective pharma-
cological induction of labour to lower the risk of caesar-
ean section. However, these studies compared induction
of labour to expectant management only, with none
evaluating the potential effects of membrane sweeping
on the process [4, 5]. Our Cochrane systematic review
found that, when compared to expectant management,
membrane sweeping is potentially associated with an in-
creased rate of spontaneous onset of labour (average RR
1.21, 95% CI 1.08 to 1.34) and a lower risk of formal in-
duction of labour (average RR = 0.73. 95% CI 0.56–0.94)
when compared with expectant management [25]. It is
not associated with increased rates of infection or pre-
mature rupture of the membranes and has the advantage
that it may be used independently or in combination
with other means of induction and can be repeated mul-
tiple times.
Guidelines by bodies including NICE [17], the Society
of Obstetricians and Gynaecologists of Canada [26] and
the Department of Health, South Australia [27], state
that women should be offered the option of membrane
sweeping at or near term. However, the optimum gesta-
tion to perform a membrane sweep to promote cervical
ripening is unknown. Further, there has been a little dir-
ect comparison of the effect of multiple membrane
sweeps versus a single membrane sweep to promote
spontaneous labour. Internationally, guidelines have
identified the need for research to clarify these uncer-
tainties [17, 28]. In addition, our recent Cochrane
systematic review found a lack of data on the optimal
timing and frequency of membrane sweeping and rec-
ommended future research in this space [25]. A cost-
effectiveness analysis, including an antenatal, intrapar-
tum, postnatal and neonatal cost analysis, comparing
membrane sweeping with expectant management and
other methods of labour induction has not been carried
out. In a time where health care providers are weighing
cost-effectiveness with quality of care, this would pro-
vide invaluable data to inform health policy and is an
important gap identified in our Cochrane Systematic re-
view [25].
Clinician’s views and acceptability of membrane
sweeping have been significantly under-represented in
research. In addition, few studies explored women’s
views of membrane sweeping. Further research to ex-
plore women’s and clinician’s experiences and views
of membrane sweeping as a method of induction of
labour is needed to support the clinical application of
this intervention and to inform future definitive
evaluations.
Methods/design
Trial aim and objective
The primary objective of the MILO Study is to assess
the feasibility of conducting a definitive randomised con-
trolled trial to examine the effectiveness, and optimal in-
tensity (timing and frequency), of membrane sweeping
to prevent post-term pregnancy. The study consists of
four work packages.
WP1: a pilot randomised trial assessing the feasibility of
conducting a definitive trial to evaluate how often and
the best time to perform a membrane sweep
WP2: health economic analysis assessing the feasibility
of conducting a trial-based economic evaluation to
examine the cost-effectiveness of membrane sweeping
WP3: a qualitative study exploring the acceptability of
the trial for women and clinicians
WP4: a study within a trial (SWAT) assessing if the
point at which women are invited to take part in the
trial (i.e. when should women be asked?) affects the
number of women recruited to and retained in the trial
Methods
The proposed feasibility study consists of four work
packages:
Work package 1: Pilot randomised trial
Methods/design
We will use a multicentre, pragmatic, parallel-group
pilot randomised controlled trial with an embedded 2 ×
2 factorial design (Fig. 1). This allows an examination of
the feasibility of a staged ‘gated’ approach to trial
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analysis in a future definitive trial. For example, it
allows us to evaluate the feasibility of a future trial to
answer the primary question ‘is membrane sweeping
effective in preventing post-term pregnancy?’ and also
address the effectiveness of different timings and fre-
quency of membrane sweeping. The advantage of
using a factorial design in the MILO Study is that we
can assess two individual questions simultaneously in
the same population.
By utilising resources dynamically, we ensure a more
efficient use of resources including sample size and time
[29]. A factorial design requires a smaller sample size
when compared to running two separate parallel trials
resulting in reduced running and management costs and
shorter time frame. The protocol has been prepared in
line with the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) guidelines (Add-
itional file 1) [30].
Fig. 1 Study design
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Setting
The MILO Study will be set in the antenatal outpatient
departments in two Irish maternity hospitals.
Participants
Inclusion and exclusion criteria Pregnant women car-
rying a live singleton foetus ≥ 38 weeks completed gesta-
tion (gestational age will be calculated from the first day
of the last menstrual period and an ultrasound examin-
ation carried out in the 2nd trimester) will be eligible.
The lie must be longitudinal, presentation cephalic and
amniotic membranes intact. Women must be ≥ 18 years
of age on enrolment. Women will need to be able to
communicate in English and give written informed con-
sent. Women with any contraindications to a vaginal
examination or vaginal birth (i.e. placenta praevia, vasa
praevia, antepartum haemorrhage or undiagnosed vagi-
nal bleeding, malpresentation, i.e. transverse lie, Herpes
simplex virus with active genital lesions or prodromal
symptoms) will be excluded from the MILO Study.
Recruitment
Written trial information will be offered to women po-
tentially eligible for participation at 35–36 + 6 week’s
gestation or at 37–38 + 6 week’s gestation, depending on
SWAT randomisation (see below), during routine ante-
natal appointments in each site. Clinicians and/or re-
search midwife at participating antenatal clinics will
identify women who are potentially eligible to participate
in the study. Women will be given an information pack
that will include a letter introducing the trial and a par-
ticipant information leaflet, which will inform potential
participants of the background and purpose of the study,
risks and benefits of participation, what participants are
being asked to do, their right to withdraw and offer to
answer any questions they have relating to the study.
This will be followed up at the 39-week antenatal visit
when the researcher will invite eligible women to
participate.
Obtaining informed consent
At the 39-week antenatal visit, the potential for inclusion
to the trial will be checked by the attending midwife
and/or research midwife. The trial will be explained, and
questions potential participants might have will be an-
swered. Eligible women will be asked to participate at
this time, and written informed consent will be obtained
from women agreeing to participate.
Randomisation and allocation concealment
Randomisation to intervention and control will be at the
level of the individual, i.e. individual randomisation,
stratified by parity and centre. Randomisation is on 2:1
ratio; that is, for every two women randomised to the
intervention arm (sweeping intervention), one will be
randomised to the control arm (usual care). Women in
the intervention group will further be randomised in a
ratio of 1:1 to the factorial design. The random alloca-
tion sequence will be generated using a computer-
generated random number list. Random permuted
blocks of sizes 6 and 12 will be used to determine the
group allocation. Randomisation will be stratified by (a)
parity to ensure appropriate representation of primipar-
ous and multiparous women to each group and (b)
centre using a separate block randomisation list for each
of the two centres. Block sizes will be concealed until
completion of the trial.
To ensure concealment of allocation, randomisation
will be done electronically using web-based random allo-
cation based on random sequence generation detailed
above. The enrolling midwife will log stratification fac-
tors with the randomisation service through a web inter-
face after which he/she will be informed of the
allocation (usual care or group allocation in the 2 × 2
factorial design) and the unique study ID number, which
will be documented on the consent form.
Blinding
Clinicians performing a membrane sweep cannot be
blinded, and it is not feasible to genuinely blind mem-
brane sweeping for women. Therefore, neither clinicians
administering the intervention nor women will be
blinded to the group assignment. Data will be reviewed
by two assessors blinded to the group allocation.
Intervention
Amniotic membrane sweeping is defined as the manual
detachment of the inferior pole of the amniotic mem-
branes from the lower uterine segment [22]. This is per-
formed with consent by a clinician digitally through a
circular motion during a vaginal examination. If the cer-
vical os is closed, massage of the cervix will be accepted.
Women will initially be randomised in a 2:1 ratio to:
 Membrane sweep (2) versus no membrane sweep (1)
Those allocated to the intervention group will then be
further randomised in a factorial fashion to A, B, C or D
(Table 1):
A. Membrane sweep at 39 weeks’ gestation only
B. Membrane sweep at 40 weeks’ gestation only
C. Membrane sweep at 39, 40 and 41 weeks’ gestation
or until the onset of labour
D. Membrane sweep at 40 and 41 weeks’ gestation or
until the onset of labour
Finucane et al. Trials          (2021) 22:113 Page 5 of 15
Control group
Women in the control arm will not receive a membrane
sweep and will receive usual care (as defined by local
hospital protocols and vaginal examination to determine
Bishop score only). Usual care in both sites is the same
and includes women attending for routine antenatal
clinic appointments monthly up to week 32, fortnightly
to week 38 and weekly to week 42. Women will be of-
fered induction of labour at approximately 41 weeks’
gestation and labour induced in most women prior to
42 weeks’ gestation. We will identify any intricacies of
usual care that might be present in each site but that
might not become apparent outside of a research con-
text as part of the study through the mapping usual care
pathways. Other than randomisation to an intervention
group or a control group, all women will receive usual
care as defined by local hospital protocols. Participating
in this trial will not alter the intrapartum or postnatal
care pathway for the woman or her infant.
Withdrawal from trial/treatment or protocol deviation post-
randomisation
If a woman decides to leave the trial after randomisation,
she will be withdrawn from the trial and will receive
usual maternity care as defined by local hospital policy.
The same strategy will be implemented for protocol vio-
lations. Randomisation will take place immediately prior
to the commencement of the intervention to try and
mitigate these events. The pilot trial will use intention-
to-treat (ITT) data analysis. If a woman withdraws from
the trial, we will try to obtain consent to collect data
relevant to the study and/or routine follow-up data. In-
formation and communications will be recorded in the
trial database.
Clinician training
All necessary midwives and obstetricians will receive the
MILO training programme, which will include training
on how to perform a membrane sweep per trial defin-
ition and training on the study protocol to enable them
to support recruitment of women to the study, answer
any questions women or their partners may have,
support the taking of informed consent and randomisa-
tion of women. Recruitment will be supported by on-site
research midwife, and training of clinicians will be
dependent on the tasks they undertake. To enhance val-
idity, reliability and generalisability of the intervention,
special consideration will be given to the training of
clinicians performing a membrane sweep to ensure
treatment fidelity. We will develop a standardised inter-
vention manual, and prior to the intervention start date,
all clinicians who might perform a sweep will receive the
manual. In addition, all relevant clinicians will receive
training in the form of a tutorial video and hands-on
training from an experienced trainer. This training ses-
sion will teach a standardised protocol for the interven-
tion. Adherence to this protocol will be monitored
throughout the trial by the research midwife and the
trial project manager.
Outcome measures
We will collect the following outcome data:
Primary outcomes
The following are the outcomes relating to feasibility
assessment:
1. Recruitment: evaluation of the number and
percentage of eligible women who are recruited and
randomised to the study. Assessed by study-specific
checklists.
2. Retention: evaluation of the number and percentage
of eligible women who are randomised, take part in
and adhere to the study protocols. Data will be
extracted from routinely collected data.
3. Adherence with the trial interventions: evaluation
of adherence with the trial interventions and
reasons for non-compliance assessed by study-
specific checklists. Data will be extracted from rou-
tinely collected data and focus group interviews
with clinicians and participants at 6 weeks post-
intervention.
4. Evaluation of the randomisation process:
evaluation of effective allocation of participants
to the intervention/control group assessed by
study-specific checklists and evaluation of the
randomisation protocol throughout the random-
isation period.
5. Evaluation of attrition rates: evaluation of
attrition rates assessed by study-specific
checklists. Data will be extracted from routinely
collected data.
Table 1 Allocation of the intervention group
Sweeping at 39 weeks Sweeping at 40 weeks
Single membrane sweeping A B
Weekly membrane sweeping (up to 41 weeks or until onset of labour) C D
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6. Evaluation of the types of attrition: evaluation of the
types of attrition assessed by case report forms.
Data will be extracted from routinely collected data.
7. Evaluation of the data collection process through
study-specific checklists: evaluated, statistically and
narratively, by assessing the completeness of the
outcome measurements at baseline and postnatal
(6 weeks) through study-specific checklists. Re-
searchers will manually examine the data collected.
They will assess the proportion of complete data
collection forms, the quality of data collected and
the applicability of this data in facilitating pilot trial
outcomes.
8. Estimate the main effect of individual intervention
components and their interactions: estimates (with
measures of uncertainty) of the main effect of
individual intervention components and any
interaction effect between the main effects of the
embedded factorial design will be assessed and
reported using regression analysis.
9. Evaluation of the data analysis process: as this is a
feasibility study, formal hypothesis testing will not
be undertaken. Researchers will manually examine
the data collected. Evaluation of the data analysis
process will be undertaken through the assessment
of gaps and limitations to the analysis process
measured by study-specific checklists. Findings will
be reported through descriptive statistics and
graphical summaries.
10. Evaluation of the EQ 5D: assessment of the
mechanism of, timing of and delivery of the EQ 5D
through study-specific checklists.
11. Feasibility of cost analysis process through analysis
of study-specific documentation: assessment of data
collection tools to undertake cost-effectiveness ana-
lysis through study-specific documentation. Re-
searchers will manually examine the data to assess
the mechanism of, timing of and delivery of the cost
analysis tools.
12. Feasibility of the cost-effectiveness analyses: assess-
ment of the mechanism and utilisation of the incre-
mental cost-effectiveness ratio (ICER), through
study-specific checklists.
Clinical outcomes
This study will also collect clinical and adverse outcome
data that are likely to be collected in the future definitive
trial. This is done not to evaluate the clinical effective-
ness of membrane sweeping within a pilot trial but to
test the outcome collection processes and to help inform
the sample size estimates for and safety of a future de-
finitive study. Data will be extracted from routinely col-
lected data. These outcomes are as follows.
Primary outcome (of future definitive trial) The pri-
mary outcome is the number of participants achieving a
spontaneous onset of labour.
Maternal secondary outcomes
 Number of participants who underwent an
induction of labour: formal induction of labour
using pharmacological or surgical methods.
 Number of participants achieving a spontaneous
vaginal birth: spontaneous vaginal birth.
 Instrumental birth: vaginal birth which is assisted
with the use of instruments.
 Caesarean section: birth which is achieved through
the surgical procedure caesarean section.
 Post-partum haemorrhage ≥ 500 ml: blood loss ≥
500mls within the first 24 h of the birth of a baby.
 Ante-partum haemorrhage requiring hospital
admission: bleeding from the genital tract, from
24 + 0 weeks of pregnancy and before the birth of
the baby.
 Uterine hyperstimulation with/without foetal heart
rate (FHR) changes: uterine hyperstimulation
defined as uterine tachysystole (more than five
contractions per 10 min for at least 20 min) and
uterine hypersystole/hypertonicity (a contraction
lasting at least 2 min). These may or not be
associated with changes in the foetal heart rate
pattern (persistent decelerations, tachycardia or
decreased short term variability) [31].
 Serious maternal death or morbidity (e.g. uterine
rupture, admission to intensive care unit,
septicaemia).
 Epidural analgesia: introduction of a local
anaesthetic into the epidural space of the vertebral
canal.
 Augmentation of established labour: the stimulation
of uterine contractions using pharmacologic
methods or artificial rupture of the membranes to
increase their frequency and/or strength following
the onset of spontaneous labour or contractions
following spontaneous rupture of membranes.
 Pyrexia in labour: pyrexia that developed any time
after the onset of labour.
 Uterine rupture: all clinically significant ruptures of
unscarred or scarred uteri. Trivial scar dehiscence
noted incidentally at the time of surgery will be
excluded [31].
 EQ 5D-5L: EuroQol EQ 5D-5L survey instrument.
Neonatal secondary outcomes
 Serious neonatal morbidity (e.g. seizures, birth
asphyxia defined by trialists, neonatal
encephalopathy, disability in childhood, proven and
suspected neonatal sepsis)
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 Apgar score < 7 at 5 min
 Cord PH < 7.20: umbilical cord blood gas test
 Neonatal encephalopathy: (severity of hypoxic-
ischaemic encephalopathy assessed using Sarnat sta-
ging: (i) stage 1 (mild)—hyper-alertness, hyper-
reflexia, dilated pupils, tachycardia and absence of
seizures; (ii) stage 2 (moderate)—lethargy, hyper-
reflexia, miosis, bradycardia, seizures, hypotonia with
weak suck and Moro reflexes; and (iii) stage 3
(severe)—stupor, flaccidity, small to mid-position
pupils which react poorly to light, decreased stretch
reflexes, hypothermia and absent Moro reflex)
 Perinatal death: (the perinatal period is defined as
‘commences at 22 completed weeks (154 days) of
gestation and ends seven completed days after birth.’
[32])
 Admission to neonatal intensive care unit (NICU) or
equivalent
Maternal and neonatal process outcomes
 Length of time from membrane sweep to the birth
of a baby
 Length of time from formal induction of labour to
the birth of a baby
 Overall length of maternal hospital stay
 Length of infant stay in NICU or equivalent
Baseline data to include age, obstetric history, parity
and Bishop Score will be collected for all participants on
the first vaginal exam at the time of randomisation.
Statistical methods and analysis
Sample size for pilot trial As this is a pilot trial and
not designed to evaluate the clinical effectiveness, we
will not undertake a formal power analysis for sample
size. We will seek to recruit 66 women per clinical site
(132 women in total) over a 6-month period beginning
in July 2020. This target represents 10% of that required
for the definitive trial (see below) and is greater than
that recommended as the minimum sample sizes for
pilot studies [33]. Data obtained from this study will in-
form the power analysis for a definitive trial.
Sample size for definitive trial The primary outcome
for the definite trial will be the spontaneous onset of
labour. National data demonstrate a spontaneous onset
of labour rate of 54% in women without routine
membrane sweeping to prevent post-term pregnancy. A
sample size of 910 in the intervention arm and 455 in
the control group (2:1 randomisation, 1365 total) will
have sufficient power (at > 80%) to detect a 15% relative
increase in the primary outcome measure, that is from
54% without membrane sweeping to 62% with
membrane sweeping. These calculations assume alpha of
0.05 and the test is 2-tailed.
Criteria for progressing to the main definitive trial
The criteria for progressing to a future definitive trial
are based on the primary feasibility objectives of the
pilot trial. The pilot will be deemed suitable to continue
to definitive trial when the following are achieved:
(a) Recruitment
 At least 30% of eligible women agree to
participate in the trial and 130 women are
randomised.
(b) Completeness of outcome data
 Complete clinical outcome data that would be
collected in the main trial collected from at least
90% of pilot trial participants.
(c) Clinician willingness to participate
 At least 70% of participating clinicians within the
two pilot sites agree that they would be happy to
implement the MILO Study. Clinician’s views,
experiences and acceptability of the MILO Study
will be explored within focus group interviews.
Given the primary objective of the MILO Study is to
assess the feasibility of conducting a definitive rando-
mised controlled trial, we will evaluate recruitment and
retention, adherence to the MILO protocol and reasons
for non-compliance, and clinicians and women’s views,
experiences and acceptability of the MILO Study. In the
event the MILO Study does not meet the above criteria,
these results will inform whether and how the design of
the definitive trial as originally envisaged should be de-
livered or adapted.
End of trial discontinuation criteria
Individual participant
 Withdrawal of informed consent
 Development of exclusion criteria or other safety
reasons during the study
 Incorrect enrolment or randomisation of the
participant (data retained for purpose of analysis)
 Unanticipated adverse event (consideration given to
whether the participant should be discontinued)
Recruitment centre
 Not reaching pre-specified recruitment targets (at
least 30% of eligible women agree to participate in
the trial and 130 women are randomised)
 Systemic non-adherence to protocol
Trial If IDMC requires termination of the study, e.g. fu-
tility analyses show no benefit to ongoing recruitment.
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For the woman, the pilot trial is considered ended on
discharge from the maternity hospital. For the infant,
the pilot trial is considered ended on discharge from the
maternity hospital or from the neonatal unit.
Co-enrolment
Women enrolled in this trial may not take part in other
interventional trials during the antenatal or intrapartum
period evaluating induction of labour or cervical
ripening.
Data collection, management and analysis
A data management plan will be completed outlining
the data management process prior to the collection and
analysis of study data.
Data collection forms Paper forms will be used in each
participating site to confirm eligibility prior to random-
isation and to record informed consent. Data will be col-
lected from the participating maternity hospitals using
paper-based case report forms (CRFs). Data will be col-
lected retrospectively by the research midwife in each
site. The participating sites will collect the woman’s hos-
pital number, and this may be used in the process of col-
lecting missing data. With the exception of the on-site
research midwife, the research team will only have ac-
cess to a unique identifier for the participant for the pur-
pose of data management. Clinical outcomes are
recorded in a woman’s health care records, i.e. gestation,
number of sweeps performed and gestation of woman at
the time of membrane sweep, hyperstimulation, mode of
delivery, analgesia, Apgar scores, length of stay and in-
fant admission to NICU. This retrospective data from
the clinical notes and the CRF are considered source
data.
Storage of data All identifiable information will be held
on a secure, password-protected database accessible only
to pre-defined personnel. Paper forms with identifiable
information will be held in secure, locked filing cabinets.
Personal data collected during the trial will be handled
and stored in compliance with the 2018 General Data
Protection Regulation (GDPR). Participants will be iden-
tified by a given code only. Data from the randomisation
paper form, CRF and outcome data collected from
women’s notes will be entered onto a purposefully de-
signed Excel database, within 7 days of the woman’s dis-
charge, by the research midwives. All entries to the
database will be recorded and dated and each version ar-
chived to ensure good clinical practice. Entered data will
later be double-checked against original forms for accur-
acy. All paper forms and data checking records will be
securely archived after completion of trial as per require-
ments under the General Data Protection Regulation EU
2016/679. Direct access to the source data/documents
will be required for trial-related monitoring by
authorised personnel only.
Data analysis All data will be analysed and reported in
accordance with the 2010 CONSORT Extension State-
ment for the reporting of Pilot and Feasibility studies
[34]. As this is a feasibility study with a relatively small
sample size, formal hypothesis testing is not appropriate;
rather, the purpose of any analyses will be to generate
estimates to inform the planning of the definitive future
trial. Suitable descriptive statistics and graphical sum-
maries will be used to summarise participant character-
istics. Means and standard deviations will be used for
continuous variables and counts and percentages for cat-
egorical variables. Estimates of variation in main effects
will be used to inform future sample size calculations.
Estimates (with measures of uncertainty) of any inter-
action effect between the main effects of the embedded
factorial design will also be undertaken. These will refine
the design characteristics of the future definitive trial.
Reporting serious adverse events
Membrane sweeping has been found to be a low-risk
intervention with no increased risk of infection or pre-
mature rupture of membranes. All adverse events will be
reported to the trial team and recorded on the woman’s
CRF. In addition, adverse events will be documented in
the participant’s health records. An expected adverse
event is discomfort during the membrane sweeping
procedure.
Work package 2: Health economic analysis
As this is a pilot trial, we will not undertake a formal
economic evaluation. The health economic analysis will
assess the feasibility of conducting a trial-based eco-
nomic evaluation to examine the cost-effectiveness of
membrane sweeping relative to expectant management
and other methods of induction of labour to prevent
post-term pregnancy. The basic tasks of economic evalu-
ation are to identify, measure, value and compare the
costs and outcomes of the alternative strategies being
considered. The pilot study explores the feasibility of
conducting an economic evaluation in this context and
will seek to inform the design of the economic evalu-
ation to be conducted alongside the definitive RCT. Evi-
dence collected on resource use and outcome measures
alongside the pilot RCT will provide the basis for the
analysis. With respect to costing, a healthcare service
perspective will be adopted, and the study will seek to
identify the healthcare resource items that are relevant
in this case. In particular, resource use associated with
the implementation of the membrane sweeping interven-
tion and the alternative expectant management and
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pharmacologic control strategies will be identified, mea-
sured and costed. In addition, other resource use over
the course of the pregnancy in respect of antenatal,
intrapartum and postnatal care will be identified, mea-
sured and costed. Unit costs will be identified and ap-
plied to convert data on resource use to resource costs,
and total cost variables will be calculated. The pilot will
involve the development and testing of appropriate data
collection tools to undertake this process. For the pilot
cost-effectiveness analysis, the alternative strategies will
be compared on the basis of the clinical outcome data
identified in the pilot RCT. This will inform costing
models for the future definitive trial. For the cost-utility
analysis, quality-adjusted life years (QALYs) will be
modelled using the EuroQol EQ 5D-5L survey instru-
ment. The pilot study will explore the feasibility, suit-
ability and appropriate timing and delivery of the EQ
5D-5L in this context. To complete the pilot study, an
incremental analysis will be conducted to model the
mean costs and mean effect comparisons of the mem-
brane sweeping intervention relative to the control strat-
egies, which will inform the analysis models in the
definitive trial. Univariate and multivariate sensitivity
analyses, in addition to probabilistic methods through
the estimation of cost-effectiveness acceptability curves,
will be employed to explore uncertainty.
Work package 3: Qualitative descriptive study
O’Cathain et al. [35] note the contribution qualitative re-
search can make to feasibility studies by exploring un-
certainties associated, for example, with interventions,
trial methodology and outcome measures, prior to the
conduct of a definite trial. Drawing on the guidance
O’Cathain et al. [35] offer for such qualitative work, this
feasibility study will include a qualitative descriptive
study to explore the acceptability and feasibility of the
MILO Study. This will include the clinician and
women’s views of membrane sweeping, relevance and
acceptance of the clinician training programme, and po-
tential barriers and enablers to recruitment for a defini-
tive trial.
Design
This work package will use a qualitative descriptive
study design. Qualitative descriptive studies aim to ex-
plore and to understand the perspectives of those dir-
ectly involved in certain processes or phenomenon [36],
and so this design lends itself well to an exploration of
the views of key stakeholders participating in the MILO
Study.
Participants
Purposeful sampling will be used. Up to 10 women per
clinical site (this target represents 15% of MILO
participants) and all clinicians participating in the pilot
trial will be invited to participate in the focus group in-
terviews. All potential participants will be contacted via
letter when the last trial participant has been discharged
from the maternity unit and invited to participate in one
of two focus groups based on their geographical loca-
tion. All letters will make clear the number of partici-
pants required. The experiences and views of women
across the control and intervention groups will be ex-
plored in order to provide an insight into all aspects of
the feasibility study.
Data collection
Data will be collected via focus group interviews carried
out in each participating site with two focus groups for
each of clinicians and women stakeholders (four focus
groups in total). The sessions will be led by an experi-
enced qualitative researcher. A topic guide, informed by
the purpose of the study and by the literature, will be
used to guide the focus groups.
Data analysis
Focus groups will be audio-recorded, and recordings will
be transcribed verbatim and entered into Nvivo. A
pseudonym will be given for each participant and will be
used on all transcripts of interviews. Data will be ana-
lysed using the framework method, a method of analysis
for qualitative data described by [37]. Identified themes
will inform the design of a future definitive trial.
Work package 4: Study within a trial
Background
Adequate recruitment of trial participants is essential to
the success of all trials. Yet, two thirds of trials will not
complete recruitment within their stated time frame
[38]. Pregnant women in particular remain underrepre-
sented in clinical research, and the recruitment of preg-
nant women to trials has proved challenging [39]. A
2018 Cochrane systematic review examining the
methods to improve recruitment to randomised con-
trolled trials found a distinct knowledge gap in evidence-
based recruitment strategies [40]. A study within a trial
(SWAT) provides an opportunity to increase the evi-
dence base about trial processes (e.g. recruitment and
retention).
Aim
To evaluate the effect of the timing of the invitation to
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Setting
As per host pilot trial
Participants
As per host pilot trial
Intervention
Group 1: Participant recruitment at 35–36 weeks + 6
days gestation
Group 2: Participant recruitment at 37–38 weeks + 6
days gestation
Randomisation
To minimise the impact of the embedded SWAT on the
design and conduct of the definitive trial, randomisation
to the different timings of recruitment will be conducted
at the site level, i.e. site randomisation. Each of the 2
sites will be randomised to recruit women from group 1
or group 2.
Recruitment
Identifying potential participants Clinicians at par-
ticipating antenatal clinics will identify potential par-
ticipants that meet the study inclusion criteria.
Written trial information will be offered to women
potentially eligible for participation at 35–36+6 week’s
gestation OR 37–38+6 week’s gestation, dependent on-
site randomisation in the SWAT, during routine ante-
natal appointments. Women will be given an informa-
tion pack, which will include a letter introducing the
trial and a participant information leaflet, which will
inform participants of the background and purpose of
the study, risks and benefits of participation, what
participants are being asked to do, their right to with-
draw and offer to answer any questions they have re-
lating to the study. This will be followed up at the
39-week antenatal visit when the researcher will invite
eligible women to participate.
Obtaining informed consent
At the 39-week antenatal visit, potential for inclusion
to the trial will be checked by the attending clinician
and/or research staff. The attending clinician and/or
research staff (we expect this will be the researcher
unless at the request of clinical staff) will be available
to explain the trial and answer any questions poten-
tial participants might have. Eligible women will be
asked to participate at this time and written informed




 Evaluation of randomisation, allocation and
concealment processes through focus group
interviews and data extracted from routinely
collected data
 Estimate variable parameters to inform sample size
for definitive trial, including standard deviation of
the outcome measure
Secondary outcomes
 Proportion of eligible women recruited. Data will be
extracted from routinely collected data.
 Proportion of recruited women that complete trial.
Data will be extracted from routinely collected data.
Sample size
As per host trial Table 2 outlines the schedule of enrol-
ment, interventions and assessments within The MILO
Study.
Ethical and safety considerations
Independent data monitoring committee We will es-
tablish an independent data monitoring committee
(IDMC) to monitor data emerging from the MILO
Study. The IDMC will meet regularly (as required) to as-
sess trial progress based on independent trial data.
Ethical approval
The MILO Study will be conducted in full conformance
with the principles of the Declaration of Helsinki and to
Good Clinical Practice (GCP) guidelines. We have
sought and obtained ethical approval from both study
sites (University Maternity Hospital Limerick and the
Coombe Women and Infants University Maternity
Hospital).
Discussion
Conducting a feasibility study prior to a definitive trial
potentially reduces the risk of research waste through
evaluation of trial processes such as recruitment and re-
tention, randomisation, intervention compliance and
data management. In 2009, Chalmers and Glasziou, esti-
mated that 85% of all health research is being avoidably
wasted [41]. Poor question choice, inappropriate trial de-
sign and inaccurate reporting of results have all contrib-
uted to research waste [42]. Worldwide, significant
public funding is allocated to support biomedical and
clinical research [43]. In the USA, the National Institutes
of Health (NIH) invests approximately US$39.2 billion a
year in medical research [44]. In 2015/2016, the National
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Institute for Health Research (NIHR) invested £247 mil-
lion [45]. Demands to improve the efficiency and effect-
iveness of public expenditure have increased pressure on
publicly funded research budgets. For clinical trials to be
sustainable, methods to reduce costs and increase prod-
uctivity must be prioritised. The publication of feasibility
study findings inform the design of definitive trials redu-
cing the risk of future research waste.
Induction of labour is often viewed as a ‘common’
intervention with approximately one in four pregnancies
ending in an induction of labour [2]. Membrane sweep-
ing potentially offers a low risk, effective intervention to
prevent a formal induction of labour that is routinely of-
fered to pregnant women. However, despite this, its ef-
fectiveness (including optimal timing and frequency) to
prevent a formal induction of labour is unknown [25].
With the MILO Study, we will evaluate the feasibility of
conducting a definitive randomised trial to assess the
safety and effectiveness of membrane sweeping in pre-
venting a formal induction of labour in women at or
near term.
To maximise sample size efficiency and cost-
effectiveness, we chose to utilise a factorial design which
will assess these questions simultaneously using the
same population [29]. The MILO Study will be con-
ducted in the antenatal department of two large mater-
nity hospitals. Mindful of minimising the impact of the
trial on the participating clinical sites, we designed all
components of the study, including intervention timings,
to align with the usual care pathway of pregnant women
attending these hospitals. Although when developing the
methodology for the MILO Study we did not expect to
conduct the trial during a pandemic, this design has
proved advantageous as it ensures that women taking
part in the trial will not be required to attend additional
antenatal appointments, while also maximising the po-
tential population from which the study will recruit.
The onset of the COVID-19 pandemic caused signifi-
cant changes to clinical practice, presenting unforeseen
challenges to clinical trials. The MILO Study, like many
trials, has had to pause recruitment, and we have
adapted its design to facilitate and overcome these chal-
lenges. These adaptations are focused on minimising
avoidable face-to-face contact.
Initially, during the recruitment of potential partici-
pants, we had planned to provide a private room in
which to answer queries on the MILO Study. However,
due to the current national guidelines, this will no longer
be feasible. To support recruitment and informed con-
sent, we will now offer women, through a letter con-
tained in the information pack, the option to engage
with the research team through scheduled calls. Women
will not be asked to provide consent during these calls;
the purpose of these calls is to facilitate further
Table 2 Schedule of enrolment, interventions and assessments within the MILO Study
Time point Study period









Postnatal period (after last
study participant is
discharged from maternity)
Postnatal period (6 weeks
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information on the MILO Study if requested. In
addition, we had planned to offer the option of face-to-
face or online focus group interviews with women and
clinicians (WP3—qualitative descriptive study). Inter-
views will now be facilitated online or by phone, either
as a one-to-one meeting or within a group setting.
In conclusion, the findings of the MILO Study, includ-
ing the views of women and clinicians, will inform the
design of a future definitive trial to examine the effect-
iveness, and optimal intensity (timing and frequency), of
membrane sweeping, a common intervention in mater-
nity care, to prevent post-term pregnancy.
Trial status
The MILO Study will begin recruiting in February 2021.
It is anticipated that recruitment will be completed in
September 2021.
Protocol version: 05 January 2021, version 1.2
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13063-021-05043-9.
Additional file 1. : SPIRIT 2013 Checklist: Recommended items to
address in a clinical trial protocol and related documents.
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AE: Adverse event; AR: Adverse reaction; IOL: Induction of labour; PPH: Post-
partum haemorrhage; PROM: Preterm premature rupture of membranes;
PPROM: Preterm premature rupture of membranes; SVD: Spontaneous
vaginal delivery; APH: Antepartum haemorrhage; CS: Caesarean section;
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